Commerzbank Aktiengesellschaft Alnylam Pharmaceuticals, Inc. Transaction History

Commerzbank Aktiengesellschaft

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 17, 2019	SELL	$70.9 - $87.82 $433,199 - $536,580	-6,110 Closed	0 $0
Q2 2019 Oct 03, 2024	BUY	$65.86 - $92.79 $402,404 - $566,946	6,110 New	6,110 $443,000
Q2 2019 Jul 23, 2019	BUY	$65.86 - $92.79 $251,321 - $354,086	3,816 Added 166.35%	6,110 $443,000
Q1 2019 Oct 03, 2024	BUY	$72.76 - $93.45 $166,911 - $214,374	2,294 New	2,294 $214,000
Q1 2019 May 13, 2019	SELL	$72.76 - $93.45 $211,149 - $271,191	-2,902 Reduced 55.85%	2,294 $214,000
Q4 2018 Oct 03, 2024	BUY	$62.67 - $88.33 $325,633 - $458,962	5,196 New	5,196 $379,000
Q4 2018 Feb 06, 2019	BUY	$62.67 - $88.33 $157,364 - $221,796	2,511 Added 93.52%	5,196 $379,000
Q3 2018 Oct 04, 2024	BUY	$87.52 - $122.67 $234,991 - $329,368	2,685 New	2,685 $235,000
Q3 2018 Nov 13, 2018	BUY	$87.52 - $122.67 $21,792 - $30,544	249 Added 10.22%	2,685 $235,000
Q2 2018 Oct 04, 2024	BUY	$88.31 - $107.8 $215,123 - $262,600	2,436 New	2,436 $240,000
Q2 2018 Aug 10, 2018	BUY	$88.31 - $107.8 $215,123 - $262,600	2,436 New	2,436 $240,000

670

112M

839K

771K

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Commerzbank Aktiengesellschaft , based on Form 13F filings with the SEC.

Stay updated on Commerzbank Aktiengesellschaft with notifications on news.